TY - JOUR
T1 - Antiviral CD8+ T-cell immune responses are impaired by cigarette smoke and in COPD
AU - Chen, Jie
AU - Wang, Xinyuan
AU - Schmalen, Adrian
AU - Haines, Sophia
AU - Wolff, Martin
AU - Ma, Huan
AU - Zhang, Huabin
AU - Stoleriu, Mircea Gabriel
AU - Nowak, Johannes
AU - Nakayama, Misako
AU - Bueno, Marta
AU - Brands, Judith
AU - Mora, Ana L.
AU - Lee, Janet S.
AU - Krauss-Etschmann, Susanne
AU - Dmitrieva, Anna
AU - Frankenberger, Marion
AU - Hofer, Thomas P.
AU - Noessner, Elfriede
AU - Moosmann, Andreas
AU - Behr, Jürgen
AU - Milger, Katrin
AU - Deeg, Cornelia A.
AU - Staab-Weijnitz, Claudia A.
AU - Hauck, Stefanie M.
AU - Adler, Heiko
AU - Goldmann, Torsten
AU - Gaede, Karoline I.
AU - Behrends, Jochen
AU - Kammerl, Ilona E.
AU - Meiners, Silke
N1 - Funding Information:
Acknowledgements: We kindly acknowledge the generous gift of the IAV strain PR8 from Susanne Herold (Justus Liebig University, Excellence Cluster Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Gießen, Germany) and the provision of the IAV-specific T-cell hybridoma clone 4VA1 by David Canaday (Case Western Reserve University, Cleveland, OH, USA). Moreover, we are grateful for the expert support by Beatrix Steer (Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germany). We thank the NIH Tetramer Core Facility (contract number 75N93020D00005) for providing the IAV tetramers. The graphical abstract was generated with BioRender. We gratefully acknowledge the provision of human biomaterial and clinical data from the CPC-M bioArchive and its partners at the Asklepios Biobank Gauting, the LMU Hospital and the Ludwig-Maximilians-Universität München. We are grateful to the excellent technical assistance of Frauke Koops, Gesine Rode and Christian Rosero (Research Center Borstel). We also like to thank Margrit Kernbach and Stefanie Fox from the BioMaterialBank North (Borstel, Germany), for their excellent technical assistance, and the study centre of the Research Center Borstel for their help. We thank the patients and their families as well as the healthy blood donors for their support.
Funding Information:
Support statement: The study was supported by funding from the Faculty of Medicine at LMU (FöFoLe program for S. Haines), the European Respiratory Society (ERS) (short-term fellowship for I.E. Kammerl), intramural funding by the Helmholtz Center Munich, and the German Federal Ministry of Education and Research, Germany (BMBF) grant EXASENS (13N13856) (funding M. Wolff) to S. Krauss-Etschmann. J. Chen was supported by the National Natural Science Foundation of China (81600063). H. Zhang is supported by China Postdoctoral Science Foundation (2022M720916). M. Nakayama was supported by the Uehara Memorial Foundation and Shiga University of Medical Science. S. Meiners is funded through a personal grant by the Leibniz foundation. Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
Conflict of Interest: H. Ma reports support for the present manuscript from the German Center for Lung Research (DZL). M. Nakayama reports overseas grant from Uehara Memorial Foundation ( Japan) and overseas grant from Shiga university of Medical Science, outside the submitted work. A.L. Mora reports support for the present manuscript from NIH (NIH U01 HL1455550-01 and NIH NHLBI R01 HL149825). J.S. Lee reports participation on clinical adjudication committee with Janssen R&D, outside the submitted work. S. Krauss-Etschmann reports support for the present manuscript from the German Center for Lung Research. K. Milger reports consulting fees and lecture honoraria from AstraZeneca, GSK, Janssen, Novartis and Sanofi, outside the submitted work. C.A. Staab-Weijnitz reports support for the present manuscript from Helmholtz Association, German Center for Lung Research (DZL) and Deutsche Forschungsgemeinschaft (DFG) within the Research Training Group GRK2338. K.I. Gaede reports support for the present manuscript from Research Center Borstel – Leibniz Lung Center – BioMaterialBank North, Airway Research Center North, German Center for Lung Research (DZL), PopGen 2.0 Network (P2N). K.I. Gaede also holds a leadership role as member of the Board of Directors of the TMF (www. tmf-ev.de), outside the submitted work. I.E. Kammerl reports support for the present manuscript from ERS (Short Term Fellowship). All other authors have no potential conflicts of interest to declare.
Publisher Copyright:
© 2023 European Respiratory Society. All rights reserved.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - BACKGROUND: Virus infections drive COPD exacerbations and progression. Antiviral immunity centres on the activation of virus-specific CD8+ T-cells by viral epitopes presented on major histocompatibility complex (MHC) class I molecules of infected cells. These epitopes are generated by the immunoproteasome, a specialised intracellular protein degradation machine, which is induced by antiviral cytokines in infected cells. METHODS: We analysed the effects of cigarette smoke on cytokine- and virus-mediated induction of the immunoproteasome in vitro, ex vivo and in vivo using RNA and Western blot analyses. CD8+ T-cell activation was determined in co-culture assays with cigarette smoke-exposed influenza A virus (IAV)-infected cells. Mass-spectrometry-based analysis of MHC class I-bound peptides uncovered the effects of cigarette smoke on inflammatory antigen presentation in lung cells. IAV-specific CD8+ T-cell numbers were determined in patients' peripheral blood using tetramer technology. RESULTS: Cigarette smoke impaired the induction of the immunoproteasome by cytokine signalling and viral infection in lung cells in vitro, ex vivo and in vivo. In addition, cigarette smoke altered the peptide repertoire of antigens presented on MHC class I molecules under inflammatory conditions. Importantly, MHC class I-mediated activation of IAV-specific CD8+ T-cells was dampened by cigarette smoke. COPD patients exhibited reduced numbers of circulating IAV-specific CD8+ T-cells compared to healthy controls and asthmatics. CONCLUSION: Our data indicate that cigarette smoke interferes with MHC class I antigen generation and presentation and thereby contributes to impaired activation of CD8+ T-cells upon virus infection. This adds important mechanistic insight on how cigarette smoke mediates increased susceptibility of smokers and COPD patients to viral infections.
AB - BACKGROUND: Virus infections drive COPD exacerbations and progression. Antiviral immunity centres on the activation of virus-specific CD8+ T-cells by viral epitopes presented on major histocompatibility complex (MHC) class I molecules of infected cells. These epitopes are generated by the immunoproteasome, a specialised intracellular protein degradation machine, which is induced by antiviral cytokines in infected cells. METHODS: We analysed the effects of cigarette smoke on cytokine- and virus-mediated induction of the immunoproteasome in vitro, ex vivo and in vivo using RNA and Western blot analyses. CD8+ T-cell activation was determined in co-culture assays with cigarette smoke-exposed influenza A virus (IAV)-infected cells. Mass-spectrometry-based analysis of MHC class I-bound peptides uncovered the effects of cigarette smoke on inflammatory antigen presentation in lung cells. IAV-specific CD8+ T-cell numbers were determined in patients' peripheral blood using tetramer technology. RESULTS: Cigarette smoke impaired the induction of the immunoproteasome by cytokine signalling and viral infection in lung cells in vitro, ex vivo and in vivo. In addition, cigarette smoke altered the peptide repertoire of antigens presented on MHC class I molecules under inflammatory conditions. Importantly, MHC class I-mediated activation of IAV-specific CD8+ T-cells was dampened by cigarette smoke. COPD patients exhibited reduced numbers of circulating IAV-specific CD8+ T-cells compared to healthy controls and asthmatics. CONCLUSION: Our data indicate that cigarette smoke interferes with MHC class I antigen generation and presentation and thereby contributes to impaired activation of CD8+ T-cells upon virus infection. This adds important mechanistic insight on how cigarette smoke mediates increased susceptibility of smokers and COPD patients to viral infections.
UR - http://www.scopus.com/inward/record.url?scp=85166479840&partnerID=8YFLogxK
U2 - 10.1183/13993003.01374-2022
DO - 10.1183/13993003.01374-2022
M3 - Article
C2 - 37385655
AN - SCOPUS:85166479840
SN - 0903-1936
VL - 62
JO - European respiratory journal
JF - European respiratory journal
IS - 2
M1 - 2201374
ER -